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ABSTRACT
Objective: The objective is to derive an algorithm to predict a cohort
preference-based short form-6D (short form-6D) score using the eightmean
health dimension scores from the short form-36 (SF-36) when patient level
data are not available.
Methods: Health-related quality of life data (N = 6890) covering a wide
range of health conditions was used to explore the relationship between
the SF-6D and the eight health dimension scores. Models obtained using
ordinary least square regressions were compared for goodness of ﬁt and
predictive abilities on both within-sample subgroups and out-of-sample
published data sets.
Results: The models explained more than 83% of the variance in the
individual SF-6D scores with a mean absolute error of 0.040. When using
mean health dimension scores from within-sample subgroups and out-of-
sample published data sets, the majority of predicted scores were well
within the minimal important difference (0.041) for the SF-6D.
Conclusions: This article presents a mechanism to estimate a mean cohort
preference-based SF-6D score using the eight mean health dimension
scores of the SF-36. Using published summary statistics, the out-of-sample
validation demonstrates that the algorithms can be used to inform both
clinical and economic research. Further research is required in different
health conditions.
Keywords: quality of life, quality-adjusted life-years, regression modeling,
short form-36, utility.
Introduction
Health-care policy decision-makers such as the National Institute
for Health and Clinical Excellence recommend that the results of
economic evaluations in health care are presented in terms of
quality-adjusted life-years (QALY) [1]. The QALY quantiﬁes
both health-related quality of life (HRQoL) and life expectancy
and allows comparison across disparate diseases and interven-
tions [2]. Preference-based measures of health have become an
established metric to derive health state values used to calculate
QALYs. Preference-based measures of health are estimated from
values people place on different aspects of health and the overall
summary score reﬂects what is important to the general popula-
tion. Examples include the EQ-5D [3], the Quality of Well-Being
Scale [4], the Health Utility Index [5] and the short form-6D
(SF-6D) [6] that is derived from the short form-36 (SF-36)
questionnaire [7].
Economic models used to aid decision-making are often
populated by HRQoL evidence identiﬁed through literature
reviews. Nevertheless, results from clinical studies are frequently
reported using a proﬁle of scores covering different features of
health, such as physical and emotional dimensions, as opposed to
an overall index. For example, results from studies using the
SF-36 [7] instrument are generally reported as cohort summary
statistics of the eight health dimension scores that are calculated
using individual responses to the original 36 questions. The
SF-36 has been cited as the most widely used generic instrument
in the world today [8], being documented in almost 5000 pub-
lications (http://www.sf-36.org; accessed September 1 2006) with
more than 2000 citations for those published between 1988 and
2000 [9]. Because access to individual patients’ responses to the
questions in the SF-36 is required to calculate the SF-6D [6], the
majority of existing SF-36 evidence cannot be used to calculate
QALYs in economic evaluations.
Although methods are available to map from SF-36 health
dimension scores onto the Health Utility Index [10] and the
Quality of Well-being scale [11], there is currently no published
method to obtain a mean cohort preference-based SF-6D score
using summary statistics of the eight health dimensions of the
SF-36. This is a major barrier to evidence synthesis for populat-
ing economic models. The current study aims to address this
limitation and the primary objective is to derive an algorithm to
predict a cohort level preference-based SF-6D score using the
eight mean health dimension scores from the SF-36 (v2) when
patient level data are not available. This algorithm has the poten-
tial to extend the scope for undertaking economic evaluations in
health care using existing and future publications of SF-36 data
sets.
The next section of this article brieﬂy describes the SF-36 and
the data sets used in the current study. This is followed by a
description of the methods used, the models obtained and a
comparison of the models using standard techniques such as
goodness of ﬁt and predictive accuracy using both within-sample
and out-of-sample data. The ﬁnal section summarizes the results,
considers how the results may be used and identiﬁes areas of
future research.
Methods
The SF-36
Developed in the United States, the SF-36 is a multi-purpose
health survey that uses 36 questions to represent eight of the
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most important health concepts included in the medical out-
comes study [12,13]. The most commonly reported statistics are
the eight health dimensions: physical functioning (PF), role-
physical (RP), bodily pain (BP), general health (GH), vitality
(VT), social functioning (SF), role emotional (RE) and mental
health (MH) that are calculated using responses to the SF-36
questionnaire. Each dimension consists of several items or ques-
tions. For example, the physical function dimension has 10 items
to which the respondent can make one of the three responses:
“limited a lot,” “limited a little” or “not limited at all,” coded 1,
2 or 3, respectively. The traditional method of scoring involves
re-coding responses to ensure that higher scores mean better
health and summing items in a dimension to produce a raw
dimension score (10–30) that is then transformed onto a 0–100
scale. Although these statistics can provide information on the
effectiveness of health-care interventions, the scoring algorithms
do not incorporate preferences and have not been designed for
use in economic evaluations.
The SF-6D
Brazier et al. [6,14] constructed a preference-based measure of
health from the SF-36 that reduces the outcomes to a single
preference-based measure of health, the SF-6D. The index uses
11 items selected from the SF-36 to assign a respondent to a
6-domain classiﬁcation of health states that generates 18,000
health states in total. Standard gamble valuation techniques were
used in a survey of a representative sample (n = 611) of the UK
general population to value a selection of 249 states. These data
were modeled to produce an algorithm to derive a single index
for the full set of health states deﬁned by the SF-6D. Scored on a
continuous index ranging from 0.296 to 1, 0.296 represents the
maximum impaired level on all six dimensions, and 1 represents
“full health,” i.e., the least impaired level on all six dimensions.
The SF-6D was formulated to be used to represent health state
values in economic evaluations and requires individual level
responses to the SF-36 (http://www.shef.ac.uk/scharr/sections/
heds/mvh/sf-6d).
The Data Sets Used in the Regressions and
Within-Sample Validation
Data (N = 6890) was pooled from 15 studies used in previous
research in the School of Health and Related Research. These
data were used because they included the individual responses to
the questions in the SF-36 and thus could be used to derive the
eight mean dimension scores of the SF-36 and the single utility
index from the SF-6D for both individual patients and cohorts.
The data sets were collected during observational studies, ran-
domized controlled trials and longitudinal randomized trials.
The studies cover a wide range of health conditions including
asthma [15], chest pain [16], healthy older women [17], chronic
obstructive pulmonary disease [18], menopausal women [19],
irritable bowel syndrome [20], intensive care patients [21], leg
reconstruction [22], leg ulcers [23], lower back pain [24], mental
health [25], osteoarthritis [26], sleep apnea [27], trauma patients
[28] and varicose veins[29]. Summary statistics are provided in
Table 1.
Out-of-Sample Data Sets Used to Validate the Models
Published papers that could be used to validate the models were
identiﬁed using the keywords SF 36, SF-36, short form-36, SF
6D, SF-6D, short form-6D, health, quality of life, QoL, health-
related quality of life and HRQoL. Studies were retained if they
included the mean values for the eight SF-36 health dimension
scores and the corresponding cohort mean SF-6D index score.
Statistical Methods
Although data from individuals were used to derive the predic-
tive equations, the objective was to obtain a method to predict a
mean cohort SF-6D score using mean cohort health summary
scores in contrast to predicting individual results using patient
level data. Because item response data are rarely published in
HRQoL studies, this requires that the SF-36 summary statistics
are used to create the equations rather than the individual
responses to the SF-36 questionnaire.
Ordinary least square (OLS) regressions were used to explore
the relationship between the preference-based measure and the
corresponding health proﬁle. The general model is deﬁned as:
SF D x d ri i i-6 1 2 3= + + + +α β β β ε whereby
SF-6D represents the SF-6D preference-based index, x repre-
sents the vector of main effects (continuous variables: PF, RP, BP,
GH, VT, SF, RE, MH), d represents the vector of demographic
characteristics (continuous variable: age; binary dummy variable:
Table 1 Summary statistics of the data sets used in the regressions and within-sample subgroup validations
N
Female
%
Age
Mean
SF-6D
Mean
PF RP BP GH VT SF RE MH
Mean dimension score
Full data set 6812 65 51 0.70 67.3 56.2 61.9 58.1 49.5 66.5 65.0 66.0
Asthma [15] 2494 61 50 0.70 69.4 61.7 69.3 53.7 50.1 64.7 67.2 68.1
Chest pain [16] 601 18 50 0.71 73.8 50.6 50.6 57.7 50.5 72.1 64.4 66.1
Healthy older women [17] 203 100 65 0.69 48.3 41.1 58.8 58.3 51.3 75.0 60.1 71.6
Chronic obstructive pulmonary disease [18] 87 51 65 0.62 32.1 20.4 56.2 31.9 35.9 49.4 50.2 65.9
Menopausal women [19] 657 100 53 0.76 79.9 71.5 67.7 65.8 51.9 81.5 74.0 67.9
Irritable bowel syndrome [20] 331 86 47 0.75 80.3 66.8 64.9 63.7 51.6 78.3 69.3 67.8
Intensive care [21] 147 59 57 0.63 40.9 17.2 49.7 68.3 59.3 49.8 45.6 62.1
Lower back pain [22] 198 62 43 0.64 57.6 23.6 31.3 64.3 46.2 62.1 65.0 67.4
Leg reconstruction [23] 86 68 34 0.67 42.2 39.2 48.6 61.6 54.6 60.1 57.8 68.7
Leg ulcers [24] 232 66 74 0.68 43.5 50.5 56.0 64.6 53.3 66.6 66.2 69.6
Mental health [25] 453 84 43 0.59 67.6 47.4 50.7 46.2 25.2 43.6 30.8 38.4
Osteoarthritis [26] 170 60 68 0.61 24.4 12.4 53.0 52.0 58.1 51.8 41.0 62.7
Trauma [28] 207 47 54 0.66 48.6 31.2 52.9 56.8 48.0 58.1 57.6 62.8
Sleep apnea [27] 188 68 65 0.65 50.4 43.9 49.4 48.7 40.5 67.0 61.0 59.5
Varicose veins [29] 836 72 51 0.75 83.1 75.8 68.9 70.5 57.0 73.3 82.7 73.4
Pearson correlations with SF-6D using individual patient level data
0.68 0.68 0.70 0.61 0.68 0.76 0.65 0.66
The health dimensional scales from the SF-36: BP, bodily pain; GH, general health; MH,mental health; PF, physical functioning; RE, role emotional; RP, role-physical; SF, social functioning;VT, vitality.
All Pearson correlations are signiﬁcant at 0.01 level.
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sex), r represents the vector of ﬁrst-order interactions between
the main effects (i.e. the eight squares and 28 products of the
main effects), bn represent vectors of unknown parameters, i
represents individual respondents and e represents the stochastic
error term of the regression (the residual). The models were
constructed in STATA using backward and forward eliminations.
To reduce potential problems with multicolinearity due to the
large number of interactions, a cutoff criteria (r < |0.90|) for
correlations between cross-products was used for inclusion in the
regressions. The main effects were retained in all models. The
squares and interaction variables were retained if they made
signiﬁcant contributions (P-value < 0.05) to the models and the
results were assessed using the variance inﬂation factor. The
Cook-Weisberg and the Shapiro-Wilk test were used to detect
heteroscedasticity and normality in the residuals, respectively.
Transformations were considered where heteroscedasticity was
detected (results not shown) and White’s corrected standard
errors were used where this could not be rectiﬁed. Statistical
signiﬁcance is assumed where the P-value is less than or equal to
0.05.
To assess the results generated by the models, the predicted
and actual SF-6D scores were compared using the root mean
squared error (RMSE) and mean absolute error (MAE). The
minimal important difference (MID), deﬁned as the smallest
difference in score that patients perceive as beneﬁcial, was also
used [30]. These summary measures of agreement were applied
to the results obtained using within-study subgroups and out-
of-sample data sets. The models were compared using standard
descriptive statistics (mean, standard deviation [SD], max, min)
of predicted values and the R2 statistic that quantiﬁes the
explanatory power of the model, i.e. how much of the vari-
ability in the dependent variable is captured by the predictors
used. Their predictive abilities are also compared.
Results
Within-Sample Data
Of the 6890 respondents, information for age (sex) was available
for 5633 (5720). The mean age of these respondents is 51 years
(range 16–98) and the majority (65% of 5720) are female. The
SF-6D data are approximately normally distributed (Table 1)
with mean 0.70 (median 0.71, SD 0.13; range 0.26–1). Few
individuals score extreme values on the SF-6D; 187 (1.4%) indi-
viduals have SF-6D scores 0.41 while 94 (7.5%) have scores
0.93. Data for the eight health dimension scores cover the full
possible range 0–100 (where 100 is the “best” health).
When subgrouped by study (Table 1), the mean cohort SF-6D
scores range from 0.59 (SD 0.11) for individuals enrolled in the
mental health study [25] to 0.76 (SD 0.12) for menopausal
women enrolled in a study examining the effects of hormone
replacement. [19] The SF-6D scores are signiﬁcantly correlated
with all the eight health dimension scores with social function
having the strongest relationship (Pearson correlation = 0.76,
P-value < 0.01, Table 1).
Out-of-Sample Data Sets
The search identiﬁed 10 studies (Table 2) covering a wide range
of health conditions, including asthma [31], ankylosing spondyli-
tis [32], cardiovascular disease [33–36], diabetes [36,37], lung
transplants [38], musculoskeletal diseases [39] and rheumatoid
arthritis [40]. The 10 studies provide 29 sets of data that can be
used to predict mean SF-6D scores using the eight mean health
dimension scores. Six of the studies also provide data which can
be used to compare incremental values between two or more
arms (n = 8) [27–29,31,33,36], and six of the studies provide
data which can be used to compare changes in SF-6D over time
Table 2 Summary statistics of the out-of-sample data sets used in validations
Health condition Study arm Time n SF-6D PF RP BP GH VT SF RE MH
CAD [33] S1 Base 296 0.67 62.4 38.9 61.7 62.5 48.3 69.0 59.8 79.7
Lung transplant [38] S1 Base 99 0.70 39.7 41.9 45.3 38.7 45.3 44.8 45.6 48.3
Rheumatoid arthritis [32] S1 Base 291 0.56 37.1 12.9 27.8 42.3 32.6 55.2 48.1 67.2
S1 3 months 0.63 47.6 28.7 42.5 48.3 43.6 67.5 56.6 72.8
S1 6 months 0.64 49.2 34.9 59.0 55.5 55.2 80.9 63.6 72.9
Ankylosing spondylitis [32] S2 Base 62 0.60 50.4 23.7 30.6 42.4 39.9 63.9 56.3 70.3
S2 3 months 0.75 69.2 55.8 56.2 55.7 62.8 82.6 79.1 81.5
S2 6 months 0.72 68.3 55.1 77.7 65.6 80.7 98.4 98.3 79.1
Diabetes, Chinese [36] S1 Base 91 0.76 79.7 79.4 79.7 62.3 59.4 84.5 85 72.1
Diabetes, Malays [36] S2 Base 74 0.75 72.7 69.9 73.6 65.2 67.1 78.7 75.7 77.4
Diabetes, Indian [36] S3 Base 144 0.71 74.0 73.9 72.6 69.8 64.1 77.2 75.3 71.9
Rheumatoid arthritis [40] S1 Base 86 0.56 38.7 16.1 30.0 45.3 37.5 56.4 52.6 71.2
S1 6 months 0.56 41.4 30.2 38.5 45.3 39.4 61.3 51.2 69.0
S2 Base 97 0.58 43.3 15.6 31.7 45.7 35.6 61.7 55.4 70.0
S2 6 months 0.64 53.2 38.2 45.7 53.2 47.9 76.0 72.1 78.6
No medical condition [37] S1 Base 3155 0.79 82.0 81.9 80.4 70.0 64.8 81.5 77.5 73.1
Acute medical condition [37] S2 Base 5224 0.77 80.3 80.5 78.3 68.6 63.8 80.6 79.2 72.4
Stroke [34] S1 Base 98 0.55 19.0 8.0 64.0 55.0 42.0 41.0 48.0 68.0
S1 6 months 0.68 43.0 34.0 72.0 59.0 52.0 62.0 69.0 78.0
Musculoskeletal [39] S1 Base 310 0.78 94.5 87.9 85.4 74.2 66.8 82.5 87.7 70.7
S1 EoS 0.76 92.8 83.1 75.4 73.6 65.9 81.9 84.1 70.8
Musculoskeletal free [39] S2 Base 620 0.78 94.5 87.6 86.3 73.4 66.5 83.3 86.5 70.7
S2 EoS 0.78 94.0 85.2 83.7 74.6 68.2 84.2 85.2 71.8
Asthma [35] S1 Base 220 0.70 63.1 38.1 66.4 59.4 48.8 72.6 63.3 71.2
S1 EoS 0.76 81.3 73.3 75.5 69.4 60.0 83.1 79.6 75.9
Stroke [35] S2 Base 81 0.55 17.8 8.3 62.3 54.4 41.5 42.7 47.3 67.2
S2 EoS 0.67 41.6 32.1 68.8 56.8 50.5 60.8 68.3 77.9
Asthma [31] S1 Base 241 0.63 63.2 38.7 67.2 57.9 48.2 72.1 63.3 70.7
S1 EoS 0.73 81.3 73.1 76.1 69.2 59.4 83.4 80.2 75.9
The health dimension scores from the short form-36 (SF-36): BP, bodily pain; GH, general health; MH, mental health; PF, physical functioning; RE, role emotional; RP, role-physical; SF, social
functioning;VT, vitality. Published data sets: S1, study arm 1; S2, study arm 2; S3, study arm 3; EoS, end of study.
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(n = 12) [26,27,29,31,33,36]. The mean SF-6D scores in the
out-of-sample data sets range from 0.55 for a cohort with a
history of stroke, to 0.79 for a cohort with no recorded medical
condition [34,37]. The baseline incremental SF-6D scores
(Table 2) between study arms range from 0.005 for subjects
enrolled in a longitudinal study assessing the HRQoL impact of
new onset musculoskeletal disorders to 0.142 for poststroke
patients enrolled in an observational cohort study [35,39]. The
incremental changes over time (Table 2) range from -0.001 for
patients undergoing percutaneous coronary intervention to
0.150 for patients with ankylosing spondylitis [40,32]. Further
details of the studies are available from the authors on request.
Models Estimated from Individual Level Data
The explanatory power of the model using just the eight main
effects (Table 2, model 1) is 83%. The main effects represent the
health dimension scores that increase in magnitude with better
health and the coefﬁcients for these variables are positive as
would be expected. Although all eight main effects are signiﬁ-
cant, the age and sex variables are not statistically signiﬁcant
(P-value > 0.05) in the multivariate model. Diagnostic tests
reveal potential problems with non-normal (Shapiro–Wilk test
z = 7.3, P-value < 0.001) and heteroscedastic (Cook–Weisberg
test 82 = 206, P-value < 0.001) residuals. The regression was
re-run using White’s robust standard errors and all the main
effects remained signiﬁcant [41]. When including signiﬁcant
interactions, the ﬁnal model (Table 2, model 2) has 16 indepen-
dent variables in total: the eight main effects, ﬁve squares and
three additional cross products. Model 2 explains 85% of the
variance in the SF-6D scores.
Predictive Ability UsingWithin-Sample Individual
Patient-Level Data
When predicting individual SF-6D scores (Table 3), the MAE
(RMSE) is 0.041 (0.052) for model 1 and 0.040 (0.050) for
model 2. Using model 1, 2256 (33%) and 354 (5%) of the
predicted values have errors greater than |0.05| and |0.1|, respec-
tively. Using model 2, 31% and 5% of the predicted values have
errors greater than |0.05| and |0.1|, respectively. While the
maximum predicted value is larger for model 1 (0.902) than for
model 2 (0.879), the minimum predicted value (0.344 vs. 0.301)
is also higher. Thus scores predicted using model 2 cover 78% of
the actual range in the data set compared with 75% for model 1.
Plotting the residuals, observed and predicted SF-6D data
(Fig. 1) show that model 1 underpredicts at higher levels of
health state values and overpredicts at lower levels as would be
expected. The plot also suggests that the variance in the errors
may be larger at the lower levels of health state values than at the
higher levels.
Normal quantile plots, which graph the quantiles of a vari-
able against the quantiles of a normal distribution, are sensitive
to nonnormality near the tails. Plotting the residuals in this
manner (ﬁgures not shown), the variance at the extremes
improves slightly for model 2.
Predictive Ability UsingWithin-Sample Mean Statistics
The primary objective of the study is to predict a mean
preference-based cohort score using published statistics where
individual preference-based measures are not reported. To assess
the models’ predictive ability when patient-level data are not
available, the mean values for the eight health dimensions were
used to predict a cohort-level mean SF-6D score using the full
sample and the individual data sets which were pooled. The
models were also assessed by subgrouping the data by sex, age
bands and SF-6D scores (Table 4).
When subgrouping the sample, the total mean error in the
predicted values is 0.0057 and 0.0065 for model 1 and model 2,
respectively (Table 4). The RMSE for model 2 is slightly smaller
than for model 1 at 0.0258 as opposed to 0.0320 and 28/39
(72%) of predicted values are correct to within |0.01| as opposed
to 27/39 (69%) for model 1. The least accurate scores for both
models are when the data are subgrouped by SF-6D score. Using
the mean values for individuals with SF-6D <0.3 and >0.90, both
models over-predict and under-predict health state values by
more than 0.099 and 0.068, respectively. When the full data set
is subgrouped by sex, the estimated utilities have errors of 0.000
(0.003) for women (men) when using model 1, and errors of
0.005 (0.008) for women (men) when using model 2. The errors
in the predicted values for the all female cohort (menopausal
women) are also modest: -0.012 and -0.008 for model 1 and
model 2, respectively. With one exception (>90 years), all the
results for both models are accurate to within |0.01| when the
sample is subgrouped by age band.
Predictive Ability Using Out-of-Sample Mean Statistics
The out-of-sample publications provide 29 sets of data which
could be used to assess the models’ accuracy in predicting mean
cohort SF-6D scores. The mean errors (Table 5) in the 29 pre-
dicted values are 0.0271 and 0.0265 for model 1 and model 2,
respectively, suggesting both models slightly overestimate the
Table 3 Summary of SF-6D models and statistics
Model 1 Model 2
Main effects
Main effects plus
interactions
Beta* RSE* Beta* RSE*
Constant 34.3814 0.287 30.2787 0.4221
PF 0.0994 0.0033 0.1742 0.0108
RP 0.0215 0.0021 0.0279 0.0021
BP 0.1083 0.0031 0.2456 0.011
GH 0.014 0.0038 -0.0397 0.0131
VT 0.0479 0.0046 0.1345 0.0123
SF 0.1011 0.004 0.0907 0.0038
RE 0.0394 0.0021 -0.0301 0.0076
MH 0.1269 0.0048 0.1252 0.0046
PF*PF n/a n/a -0.0007 0.0001
BP*BP n/a n/a -0.0011 0.0001
GH*GH n/a n/a 0.0005 0.0001
VT*VT n/a n/a -0.0009 0.0001
RE*RE n/a n/a 0.0007 0.0001
PF*BP n/a n/a -0.0001 0.00003
GH*SF n/a n/a 0.0002 0.00004
GH*RE n/a n/a -0.0001 0.00003
Adj R2 0.834 0.846
ME 0.000 0.000
MAE 0.041 0.040
RMSE 0.052 0.050
<|0.10| 95% 95%
<|0.05| 77% 69%
SF-6D Actual Predicted Predicted
Mean 0.698 0.698 0.698
SD 0.127 0.116 0.117
Max 1 0.902 0.879
Min 0.26 0.344 0.301
*All beta coefﬁcients and standard errors multiplied by 100.All coefﬁcients were statistically
signiﬁcant (P-value < 0.01).
BP, bodily pain;Calc, calculated using Brazier et al. [6];GH, general health;MAE,mean absolute
error;ME,mean error;MH,mental health;N/A,not applicable; PF, physical functioning;RE, role
emotional; Pred, predicted using regression models; RMSE, Root mean squared error; RP,
role-physical; RSE, robust standard errors; SD, standard deviation; SF, social functioning; SF-6D,
short form-6D;VT, vitality.
Predicting the SF-6D Index Using Published Mean Dimension Scores 349
values. The MAE (RMSE) in the predicted scores is 0.0358
(0.0432) for model 1 and 0.0348 (0.0425) for model 2. The
majority (72%) of scores are correct to within |0.05| and 62%
(59%) of values predicted using model 1 (model 2) are within the
minimal important difference (0.041) for the SF-6D index [30].
Plotting the actual SF-6D scores against the predicted values
for the within-sample subgroups and out-of-sample data sets
(Fig. 2) shows the predicted scores are reasonably accurate.
There is little loss in accuracy when using model 1 with just the
eight main effects as opposed to model 2 with the interaction
terms. The correlation between the observed and predicted
SF-6D scores for the combined subgroups is 0.951 for model 1
and 0.959 for model 2.
Accuracy in Predicting Incremental Utilities
The studies also provide eight sets of data which can be used
to assess the accuracy of the models when predicting
incremental utilities between cohorts within the same study
[32,35,36,37,39,40]. The mean error in the incremental differ-
ences in SF-6D scores is -0.012, and all errors are well within the
MID. The MAE (RMSE) is 0.0166 (0.0215) for model 1 and
0.0165 (0.0205) for model 2. Fifty per cent of the values are
correct to within |0.01| for both models.
When looking at changes in utilities over time (Table 5), the
mean error for model 1 is 0.004 while the mean error for model
2 is -0.004. All predicted differences in changes in SF-6D scores
over time are correct to within |0.05| and 83% of the errors are
within the MID.
Applying the Algorithm
An example of how the algorithms are applied is provided below
using the summary statistics for the full data set (Table 2) and
model 1 (Table 3).
SF- D PF RP
BP GH
6 34 3814 0 0994 0 0215
0 1083 0 0140 0 0
= + ∗ +( ∗ +
∗ + ∗ +
. . .
. . . 479
0 1001 0 0394 0 1269 100
∗ +
∗ + ∗ + ∗ )
VT
SF RE MH. . .
SF- D6 34 3814 0 0994 67 3 0 0215 56 2
0 1083 61 9 0 0140
= + ∗ +( ∗ +
∗ + ∗
. . . . .
. . . 58 1 0 0479 49 5
0 1001 66 5 0 0394 65 0 0 1269 66 0
100
. . .
. . . . . .
+ ∗ +
∗ + ∗ + ∗ )
SF- D6 0 70= .
Discussion
If patient-level data were available, the cohort mean SF-6D value
would be calculated using the individual scores obtained via the
algorithm by Brazier et al. [6]. Nevertheless, when only the
summary statistics of the eight health dimensions are available,
the results of this study offer a method to predict a reasonable
estimate for a cohort SF-6D score. The algorithm will provide
analysts with a method to generate QALYs in economic evalua-
tions and will allow comparison of overall HRQoL between
disease areas when the SF-6D preference-based measures are not
reported. Model 2 that includes the ﬁve squares, the three inter-
actions and the eight main effects is the recommended model
because the predicted values are slightly more accurate.
The accuracy of the models in predicting mean preference-
based values when using either within-sample subgroups or out-
of-sample statistics has been shown to be consistently good with
approximately 90% of errors smaller than |0.05|. When sub-
grouped by health condition, the actual mean SF-6D scores for
the within-samples range from 0.594 for a cohort with depres-
sion to 0.756 for a cohort of menopausal women. The actual
mean SF-6D scores for the out-of-sample data range from 0.55
for patients who have experienced a stroke to 0.79 for a cohort
with no recorded medical condition. Model 1 (2) predicts values
with errors of 0.006 (0.009), -0.012 (-0.008), 0.058 (0.054) and
-0.014 (-0.015) for these four groups, respectively. The range in
the mean cohort values and the corresponding errors in the
predicted values demonstrate that the algorithms perform well
across the full range of health conditions included. These results
are encouraging when assessing the potential generalizability to
other conditions.
Perhaps more importantly to economic analysts, the models
are also accurate (all errors smaller than |0.05|) when predicting
out-of-sample incremental values between cohorts at baseline or
changes over time. With 100% of errors between cohorts at
baseline and 83% of errors in incremental changes over time
within the minimal important difference for the SF-6D, the
models provide a mechanism to derive incremental quality-
adjusted life-years in economic evaluations used to inform
health-care policy decision-makers.
Although more complex models are possible, the primary
objective was to derive a reproducible and transparent algorithm
easily understood and applied by researchers. The basic OLS
techniques produce models with high explanatory powers at 0.83
and 0.85. These are comparable with a Bayesian approach
(R2 = 0.88) that predicts SF-6D scores from age, sex and the
SF-12 summary scores from the MCS-12 and PCS-12 [42]. The
variances explained by our simple models are also higher than
those derived using 2nd- to 4th-degree polynomials and spline
models (R2 = 0.63) to map SF-12 summary scores onto the
EQ-5D index [43].
Previous research has demonstrated that both age and sex can
be signiﬁcant predictors for HRQoL measures, with health-
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Figure 1 Residuals, observed and predicted SF-6D
values for model 1. There are 222/6890 (3.2%) of
individuals with observed SF-6D 0.90 and
62/6890 (0.9%) with observed SF-6D 0.35.
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related preference-based scores decreasing with age [44,45] and
sex [45,46]. Nevertheless, neither age nor sex were signiﬁcant
predictors in the multi-variate regressions. The results of the
within-sample subgroup analyses suggest that the omission of
these variables does not bias the results generated by the models.
As was observed in a similar exercise mapping from the SF-36
health dimensions to the EQ-5D index [47], the models under-
predict the SF-6D values at lower levels and over-predict the
SF-6D values at higher levels. This could be viewed as problem-
atic because the original preference-based SF-6D algorithm also
under-predicts the value of good health states and over-predicts
the value of poor states [6]. The minimum (maximum) possible
values are 0.344 (0.902) and 0.301 (0.879) for model 1 and
model 2, respectively. Nevertheless, the intention of the current
Table 4 Comparing the predictive ability of the models for within-sample subgroups
Calculated preference-based index Error
Actual SF-6D Model 1 Model 2 Model 1 Model 2
Full sample 0.698 0.699 0.704 0.001 0.006
Subgrouped by health condition (n = 15)
Asthma [15] 0.704 0.711 0.715 0.007 0.011
Chest pain [16] 0.709 0.697 0.699 -0.012 -0.010
Healthy older women [17] 0.688 0.687 0.693 -0.001 0.005
Chronic obstructive pulmonary disease [18] 0.622 0.616 0.618 -0.006 -0.004
Menopausal women [19] 0.756 0.744 0.748 -0.012 -0.008
Irritable bowel syndrome [20] 0.750 0.734 0.737 -0.016 -0.013
Intensive care [21] 0.634 0.627 0.630 -0.007 -0.004
Lower back pain [22] 0.642 0.645 0.642 0.003 0.000
Leg reconstruction [25] 0.669 0.652 0.655 -0.017 -0.014
Leg ulcer [24] 0.682 0.675 0.681 -0.007 -0.001
Mental health [25] 0.594 0.600 0.603 0.006 0.009
Osteoarthritis [26] 0.606 0.611 0.609 0.005 0.003
Trauma [28] 0.657 0.648 0.653 -0.009 -0.004
Sleep apnea [27] 0.647 0.650 0.654 0.003 0.007
Varicose veins [29] 0.750 0.754 0.760 0.004 0.010
Subgrouped by sex
Women 0.708 0.708 0.713 0.000 0.005
Men 0.705 0.708 0.713 0.003 0.008
Subgrouped by age bands (years)
<30 0.731 0.737 0.738 0.006 0.007
30–39.9 0.732 0.733 0.735 0.001 0.003
40–49.9 0.714 0.714 0.717 0.000 0.003
50–59.9 0.715 0.714 0.719 -0.001 0.004
60–69.9 0.690 0.691 0.697 0.001 0.007
70–79.9 0.666 0.669 0.674 0.003 0.008
80–89.9 0.669 0.668 0.672 -0.001 0.003
>90 0.625 0.663 0.669 0.038 0.044
<45 0.727 0.729 0.731 0.002 0.004
45–69.9 0.709 0.708 0.714 -0.001 0.005
70+ 0.666 0.669 0.674 0.003 0.008
Subgrouped by actual SF-6D score
<0.3 0.267 0.410 0.366 0.143 0.099
0.3–0.39 0.361 0.453 0.425 0.092 0.064
0.4–0.49 0.454 0.505 0.494 0.051 0.040
0.5–0.59 0.550 0.561 0.562 0.011 0.012
0.6–0.69 0.649 0.648 0.653 -0.001 0.004
0.7–0.79 0.746 0.749 0.755 0.003 0.009
0.8–0.89 0.835 0.815 0.819 -0.020 -0.016
0.9+ 0.929 0.861 0.851 -0.068 -0.078
<0.63 0.534 0.557 0.557 0.023 0.023
0.63+ 0.759 0.751 0.755 -0.008 -0.004
ME 0.0057 0.0065
MAE 0.0152 0.0146
RMSE 0.0320 0.0258
<|0.10| 100% 100%
<|0.05| 90% 92%
<|0.01| 69% 72%
<MID 90% 90%
ME, mean error; MAE, mean absolute error; RMSE, root mean squared error; SF, short form.
Table 5 Comparing the predictive ability of the models using out-of-
sample data sets
ME MAE RMSE <|0.10| <|0.05| <MID
Errors in cohort SF-6D scores (n = 29)
Model 1 0.0271 0.0358 0.0432 97% 72% 62%
Model 2 0.0265 0.0348 0.0425 97% 72% 59%
Errors in incremental values between study groups at baseline (n = 8)
Model 1 -0.0117 0.0166 0.0215 100% 100% 100%
Model 2 -0.0119 0.0165 0.0205 100% 100% 100%
Errors in incremental changes over time (n = 12)
Model 1 0.004 0.024 0.028 100% 100% 83%
Model 2 -0.004 0.025 0.029 100% 100% 83%
ME, mean error; MAE, mean absolute error; RMSE, root mean squared error; SF, short form.
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study is to derive an algorithm to generate mean preference-
based scores for cohorts as opposed to individual values and it
has been shown that this anomaly does not restrict the usefulness
of the models. Because there are comparatively few individuals at
either extreme in the majority of cohorts, the truncated range has
little impact on mean results.
Although the data set used covered the full possible range in
the SF-6D index and included patients with a wide variety of
diseases, there was a dearth of data at the lower end. Further
research to explore the impact on the results when including a
greater proportion of individuals at both extremes of the SF-6D
scale and additional medical conditions would be useful. In par-
ticular, including individuals with severe health conditions could
increase the generalizability of the results. Further validation of
the accuracy in predicting both baseline scores and incremental
values in different samples is also required.
Conclusion
Although individual-level data collection of the preference-based
weights is ideal, in budget- and resource-constrained health envi-
ronments the cost, time and manpower involved in primary
research is prohibitive. Increasingly meta-analyses of evidence
are being undertaken from published results rather than at the
individual level, as part of economic evaluations of health-care
interventions for agencies such as the National Institute for
Health and Clinical Excellence. This article presents a mecha-
nism to estimate preference-based SF-6D scores from the eight
mean health dimension scores derived from the SF-36 question-
naire. As far as the authors are aware, this study is unique in that
it looks at predicting a preference-based SF-6D score using pub-
lished dimension scores. Further research is required to validate
the results in different health conditions.
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